Mursla Bio Introduces Groundbreaking Liquid Biopsy Technology for Extracellular Vesicles in Cell Press

Mursla Bio has recently published a peer-reviewed paper in the interdisciplinary journal iScience, which is affiliated with Cell Press. The paper highlights the company’s innovative technology for analyzing extracellular vesicles (EV) sub-types found in biofluids like blood. EVs play a crucial role in intercellular communication and are poised to revolutionize disease diagnostics.

Titled “An electro-optical platform for the ultrasensitive detection of small extracellular vesicle sub-types and their protein epitope counts,” the paper introduces Nano-Extracellular Omics Sensing (NEXOS). This groundbreaking and scalable technology addresses previous limitations in the sensitive detection and quantification of EV proteins. The unique capabilities of NEXOS offer new insights into liquid biopsies and are expected to enhance the use of EVs in clinical contexts.

Mursla Bio is currently conducting a clinical study on liver cancer, with additional peer-reviewed papers expected to be published in support of this research. The company’s focus is on decoding extracellular vesicles to develop curative treatments for cancer. They have developed a first-of-its-kind blood test that enables non-invasive liver biopsies based on the analysis of liver-derived EVs. This test aims to replace ultrasound for monitoring liver cancer in high-risk patients in Western countries.

Recognized as the UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category, Mursla Bio is at the forefront of liquid biopsy technology. For more information, visit their website at mursla.com.